The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives.

Mol Neurodegener · 2021 · PMC8572071 · PMID 34742333

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The secondary outcomes, including CSF Aβ 42 , pTAU, Aβ 42 /pTau ratio, brain atrophy and plasma TNF-α levels, did show trends for a decrease in the treatment group, however, these measures did not reach statistical significance [ 246 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.